StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Core R&D by Quarter

Core R&D ($M)

QuarterlyAnnual

Novartis Core R&D: -$2,787M in Q3 2026, up 4.1% from a year earlier. That is the lowest of the 36 quarters on record here.

Latest, Q3 2026
-2,787
Period ended Sep 30, 2026
Change on a year earlier
+4.1%
-2,677 in Q3 2025
History
36 quarters
Since Q4 2017
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

“|| Research and development | – 5 150 | 191 | 2 230 | 6 | – 64 | – 2 787 | – 2 677”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCore R&D ($M)Year on yearSource
Q3 2026Sep 30, 2026-2,787+4.1%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026-2,653+3.9%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026-2,704+17.5%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025-2,763+10.4%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025-2,677+15.3%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 2025-2,553+12.2%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025-2,302+4.5%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024-2,502+12.1%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 2024-2,321+6.1%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024-2,276+6.9%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024-2,203+7.3%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023-2,231+6.5%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 2023-2,187+1,033.2%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 2023-2,129+986.2%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 2023-2,053+0.2%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 2022-2,094+798.7%Novartis Form 6-K (0001370368-24-000007) ↗

Cite this data

StockData. (2026). Novartis Core R&D ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-rd

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.